Clinical Scorecard: Neuroprotection in Glaucoma
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Targeting ganglion cells, axonal degeneration, and vascular support. |
| Target Population | Patients with glaucoma at risk of vision loss. |
| Care Setting | Ophthalmology clinics and research settings. |
Key Highlights
- Inhibition of the DLK/LZK pathway protects ganglion cells under high intraocular pressure.
- NAD+ depletion is a critical factor in axonal degeneration.
- Antagonizing endothelin may improve vascular support and visual field function.
Guideline-Based Recommendations
Diagnosis
- Utilize trend-based analyses for assessing visual field progression.
Management
- Consider new drug candidates targeting ganglion cell protection and axonal health.
Monitoring & Follow-up
- Implement AI-based enrichment strategies to identify fast progressors.
Risks
- High intraocular pressure remains a significant risk factor for neural damage.
Patient & Prescribing Data
Patients with glaucoma experiencing visual field loss.
Emerging therapies focus on neuroprotection and vascular support.
Clinical Best Practices
- Conduct clinical trials with innovative designs to reduce patient numbers needed.
- Focus on cluster testing to strengthen trial outcomes.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.